Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment. Issue 1 (February 2018) - Iavarone, M.; Loglio, A.; Grossi, G.; Viganò, M.; Facchetti, F.; Rumi, M.G.; Sangiovanni, A.; Lampertico, P.